Healthcare
Live Price
Offline$9.63
-2.53% today
1Y Change
-2.03%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cartesian Therapeutics, Inc. (RNAC) is a Healthcare stock with a market cap of $160.00M and listed on NASDAQ. The stock last traded around $9.63 and down 2.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -92.8%, EPS growth of -67.9%, a dividend yield of 0.0%. What stands out right now is revenue -92.8%, EPS -67.9%, free cash flow -142.3% with operating margin -5144.5% and ROIC -31.1%. Valuation already assumes a fairly strong business story at price/sales 92.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RNAC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNAC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RNAC Max Drawdown
-57.59%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RNAC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$85.1M
-23.2% YoY
FY Net Income
-$25.7M
-172.6% YoY
Free Cash Flow
-$61.5M
-87.2% YoY
Revenue Growth
-92.8%
EPS Growth
-67.9%
Gross Margin
-621.0%
Net Margin
-8550.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3M | 39M | 26M | 111M | 85M |
| Gross Profit | 3M | 39M | 26M | 109M | 85M |
| Operating Income | -87M | -44M | -86M | 15M | -5M |
| EBITDA | -87M | -76M | -235M | 40M | -5M |
| Net Income | -130M | -77M | -220M | 35M | -26M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 125M | 213M | 77M | 106M | 114M |
| Total Assets | 296M | 435M | 305M | 166M | 160M |
| Total Liabilities | 423M | 442M | 745M | 72M | 137M |
| Shareholder Equity | -126M | -7M | -440M | 94M | 23M |
| Total Debt | 13M | 14M | 11M | 38M | 35M |
| Net Debt | -112M | -199M | -66M | -69M | -79M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
60M
-90.9% YoY
Capital Expenditures
1M
+9.7% YoY
Free Cash Flow
61M
-87.2% YoY
Key ratios
Gross Margin
-621.0%
Operating Margin
-5144.5%
Net Margin
-8550.6%
ROE
194.1%
Debt / Equity
-0.08x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.